US EDWARDS COMMITTEE REFORMS

10 May 1992

The members of the Advisory Committee on the US Food and Drug Administration (the Edwards Committee) have announced that they are to reconvene in order to review the responses of the Department of Health and Human Services (which set up the committee) and of the FDA to the recommendations made in its May 1991 report.

The committee members say that they plan to produce a report on their findings by June 30, and they are asking for contributions from HHS Secretary Louis Sullivan and FDA Commissioner Kessler.

The committee members stress that their reassessment of their work and the responses to it is not intended to be a report card on the FDA's overall performance in the the past year. Instead, they say their focus will be on the recommendations which they submitted in May 1991, their continuing validity and the progress made in implementing them. The meeting could "confirm the responsibility of official oversight committees and commissions to revisit their recommendations after an appropriate interval," they add.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight